{"protocolSection": {"identificationModule": {"nctId": "NCT02278471", "orgStudyIdInfo": {"id": "141583"}, "organization": {"fullName": "Vanderbilt University Medical Center", "class": "OTHER"}, "briefTitle": "The SCCS Polypill Pilot Trial", "officialTitle": "The SCCS Polypill Pilot Trial"}, "statusModule": {"statusVerifiedDate": "2021-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-12", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2018-06-27", "type": "ACTUAL"}, "completionDateStruct": {"date": "2018-06-27", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-10-13", "studyFirstSubmitQcDate": "2014-10-28", "studyFirstPostDateStruct": {"date": "2014-10-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2019-06-25", "resultsFirstSubmitQcDate": "2019-09-11", "resultsFirstPostDateStruct": {"date": "2019-10-01", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-04-18", "lastUpdatePostDateStruct": {"date": "2021-05-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Thomas Wang", "investigatorTitle": "Director of the Division of Cardiovascular Medicine", "investigatorAffiliation": "Vanderbilt University"}, "leadSponsor": {"name": "Vanderbilt University", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "In this study the investigators will examine the effect of the polypill on medication adherence, systolic blood pressure, and LDL cholesterol over a 12 month span.", "detailedDescription": "The purpose of this study is to assess if a polypill-based approach to primary CVD prevention is feasible in a low socioeconomic status population. The study will assess whether a polypill approach is associated with better cardiovascular risk factor control compared with usual care.\n\nThe polypill will be supplied as a compounded pill containing atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg. The medications in the polypill have been extensively evaluated individually and in combination. Each of the medications in the polypill is approved by the United States Food and Drug Administration (FDA) and widely administered in the US for the treatment of and prevention of cardiovascular disease. The doses of each component medication included in the polypill are low, which should minimize the chance of any potential side-effects.\n\nIn this study we assess medication adherence, systolic blood pressure, and LDL cholesterol over a 12 month span, in subjects taking the polypill versus subjects under usual care."}, "conditionsModule": {"conditions": ["Hypertension", "Hyperlipidemia"], "keywords": ["combination pill", "polypill", "primary prevention"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 303, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Usual Care", "type": "NO_INTERVENTION", "description": "Subjects in this arm will not receive any investigational medications. They will remain on the same care that they are use to receiving."}, {"label": "Polypill", "type": "EXPERIMENTAL", "description": "The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.\n\nPolypill will be taken once daily.", "interventionNames": ["Drug: Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)"]}], "interventions": [{"type": "DRUG", "name": "Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)", "armGroupLabels": ["Polypill"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Systolic Blood Pressure", "description": "polypill versus usual care", "timeFrame": "12 months"}, {"measure": "Medication Adherence-Percentage of Pills Taken", "description": "polypill arm-evaluation via pill counts.", "timeFrame": "12 months"}, {"measure": "LDL Cholesterol", "description": "Polypill versus usual care", "timeFrame": "12 months"}], "secondaryOutcomes": [{"measure": "Systolic Blood Pressure", "description": "polypill versus usual care", "timeFrame": "2 months"}, {"measure": "Medication Adherence", "description": "polypill-percentage of pills taken, evaluated via pill counts", "timeFrame": "2 months"}, {"measure": "Drug Metabolite Profile", "description": "LC/MS/MS-based drug metabolite profile assay screen in the polypill arm.", "timeFrame": "12 months"}, {"measure": "LDL Cholesterol", "description": "polypill versus usual care", "timeFrame": "2 months"}, {"measure": "Insulin Resistance", "description": "Measurement of HOMA-IR using fasting glucose and insulin.", "timeFrame": "Baseline and 12 months"}, {"measure": "Inflammatory Profile", "description": "Plasma levels of IL-17, IFN-g, IL-6, IL-10, high sensitivity C-reactive protein, TNFa, IL-4.", "timeFrame": "Baseline and 12 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Enrolled at the SCCS site in Mobile, Alabama, obtain care at Franklin Primary Health Center, or live in the surrounding area.\n* Aged 45-75 years\n* Baseline systolic blood pressure \u2265120 mm Hg. In this open-label trial, the study physicians are permitted to prescribe any additional medication deemed appropriate to achieve blood pressure control.\n\nExclusion Criteria:\n\n* History of coronary heart disease or stroke\n* History of cancer, except for basal cell skin cancer\n* History of liver disease, not including chronic, clinically-stable hepatitis\n* Laboratory evidence of hepatic dysfunction (an alanine aminotransferase level more than two times the upper limit of the normal range)\n* Known renal disease, estimated creatinine clearance \\< 60\n* Current use of more than 2 anti-hypertensive medications\n* LDL cholesterol \u2265190 mg/dl\n* Insulin-dependent diabetes\n* Known intolerance to any of the components of the polypill\n* Potassium \\<3.4 or \\>5.5 mEq/L\n* Use of medications that interact with statins, including those affecting the cytochrome P450 system\n* Current use of diuretics for indications other than hypertension\n* Comorbidities that might be expected to limit lifespan during the 12-month follow-up period\n* Inability to provide consent.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "45 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Thomas J Wang, MD", "affiliation": "Vanderbilt Univeristy", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Franklin Primary Health Center", "city": "Mobile", "state": "Alabama", "zip": "36603", "country": "United States", "geoPoint": {"lat": 30.69436, "lon": -88.04305}}]}, "referencesModule": {"references": [{"pmid": "31532959", "type": "DERIVED", "citation": "Munoz D, Uzoije P, Reynolds C, Miller R, Walkley D, Pappalardo S, Tousey P, Munro H, Gonzales H, Song W, White C, Blot WJ, Wang TJ. Polypill for Cardiovascular Disease Prevention in an Underserved Population. N Engl J Med. 2019 Sep 19;381(12):1114-1123. doi: 10.1056/NEJMoa1815359."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Potentially eligible participants were invited to complete a baseline visit. During baseline visit, if eligibility confirmed, patients then randomized in open-label 1:1 fashion to either polypill arm or usual care arm. Only if baseline visit labs yielded an exclusionary result were participants then disqualified from further study participation.", "groups": [{"id": "FG000", "title": "Usual Care", "description": "Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers."}, {"id": "FG001", "title": "Polypill", "description": "The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.\n\nPolypill will be taken once daily.\n\nPolypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "155"}, {"groupId": "FG001", "numSubjects": "148"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "147"}, {"groupId": "FG001", "numSubjects": "128"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "20"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Usual Care", "description": "Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers."}, {"id": "BG001", "title": "Polypill", "description": "The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.\n\nPolypill will be taken once daily.\n\nPolypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "155"}, {"groupId": "BG001", "value": "148"}, {"groupId": "BG002", "value": "303"}]}], "measures": [{"title": "Age, Continuous", "description": "Mean age was the same for both the Polypill and the Usual care arms.", "paramType": "MEDIAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56", "spread": "6"}, {"groupId": "BG001", "value": "56", "spread": "6"}, {"groupId": "BG002", "value": "56", "spread": "6"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "99"}, {"groupId": "BG001", "value": "65"}, {"groupId": "BG002", "value": "164"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "56"}, {"groupId": "BG001", "value": "83"}, {"groupId": "BG002", "value": "139"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "151"}, {"groupId": "BG001", "value": "141"}, {"groupId": "BG002", "value": "292"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "11"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "155"}, {"groupId": "BG001", "value": "148"}, {"groupId": "BG002", "value": "303"}]}]}]}, {"title": "Systolic Blood Pressure", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "140", "spread": "17"}, {"groupId": "BG001", "value": "140", "spread": "18"}, {"groupId": "BG002", "value": "140", "spread": "17"}]}]}]}, {"title": "LDL Cholesterol", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "112", "spread": "37"}, {"groupId": "BG001", "value": "114", "spread": "32"}, {"groupId": "BG002", "value": "113", "spread": "34"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Systolic Blood Pressure", "description": "polypill versus usual care", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers."}, {"id": "OG001", "title": "Polypill", "description": "The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.\n\nPolypill will be taken once daily.\n\nPolypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "138", "spread": "23"}, {"groupId": "OG001", "value": "131", "spread": "21"}]}]}]}, {"type": "PRIMARY", "title": "Medication Adherence-Percentage of Pills Taken", "description": "polypill arm-evaluation via pill counts.", "populationDescription": "adherence not assessed in usual care arm; incomplete data for 27 polypill participants, resulting in 101 analyzed of 128 polypill participants who completed 12 month visits", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percentage of pills taken", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers."}, {"id": "OG001", "title": "Polypill", "description": "The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.\n\nPolypill will be taken once daily.\n\nPolypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "101"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "86", "lowerLimit": "79", "upperLimit": "93"}]}]}]}, {"type": "PRIMARY", "title": "LDL Cholesterol", "description": "Polypill versus usual care", "populationDescription": "# of participants in polypill arm analyzed (126) does not match number of polypill participants completed (128; in the participant flow overview) because we were unable to obtain LDL values at baseline for 2 Polypill participants. The lab was unable to calculate and a reflex direct LDL was not processed.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers."}, {"id": "OG001", "title": "Polypill", "description": "The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.\n\nPolypill will be taken once daily.\n\nPolypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "147"}, {"groupId": "OG001", "value": "126"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "109", "spread": "32"}, {"groupId": "OG001", "value": "98", "spread": "35"}]}]}]}, {"type": "SECONDARY", "title": "Systolic Blood Pressure", "description": "polypill versus usual care", "populationDescription": "The numbers of participants analyzed do not match those of the completed (in the participant flow overview) because this assessment was completed at baseline and 2 months; 291 patients (153 usual care, 138 Polypill) completed 2-month follow-up, whereas 275 (147 Usual Care, 128 Polypill) completed 12-month follow-up.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "2 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers."}, {"id": "OG001", "title": "Polypill", "description": "The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.\n\nPolypill will be taken once daily.\n\nPolypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "138"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "133", "spread": "19"}, {"groupId": "OG001", "value": "128", "spread": "19"}]}]}]}, {"type": "SECONDARY", "title": "Medication Adherence", "description": "polypill-percentage of pills taken, evaluated via pill counts", "populationDescription": "adherence not assessed in usual care arm; incomplete data for 32 polypill participants, resulting in 106 analyzed of 138 polypill participants who completed 2 month visits", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "percentage of pills taken", "timeFrame": "2 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers."}, {"id": "OG001", "title": "Polypill", "description": "The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.\n\nPolypill will be taken once daily.\n\nPolypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "106"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "98", "lowerLimit": "91", "upperLimit": "100"}]}]}]}, {"type": "SECONDARY", "title": "Drug Metabolite Profile", "description": "LC/MS/MS-based drug metabolite profile assay screen in the polypill arm.", "populationDescription": "Funding is no longer available to complete the analysis of biomarker measurements. In addition, no future funding is anticipated in order to complete this analysis.", "reportingStatus": "POSTED", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Subjects in this arm will not receive any investigational medications. They will remain on the same care that they are use to receiving."}, {"id": "OG001", "title": "Polypill", "description": "The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.\n\nPolypill will be taken once daily.\n\nPolypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "LDL Cholesterol", "description": "polypill versus usual care", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "2 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers."}, {"id": "OG001", "title": "Polypill", "description": "The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.\n\nPolypill will be taken once daily.\n\nPolypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "137"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "108", "spread": "35"}, {"groupId": "OG001", "value": "90", "spread": "33"}]}]}]}, {"type": "SECONDARY", "title": "Insulin Resistance", "description": "Measurement of HOMA-IR using fasting glucose and insulin.", "populationDescription": "Funding is no longer available to complete the analysis of biomarker measurements. In addition, no future funding is anticipated in order to complete this analysis.", "reportingStatus": "POSTED", "timeFrame": "Baseline and 12 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers."}, {"id": "OG001", "title": "Polypill", "description": "The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.\n\nPolypill will be taken once daily.\n\nPolypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Inflammatory Profile", "description": "Plasma levels of IL-17, IFN-g, IL-6, IL-10, high sensitivity C-reactive protein, TNFa, IL-4.", "populationDescription": "Funding is no longer available to complete the analysis of biomarker measurements. In addition, no future funding is anticipated in order to complete this analysis.", "reportingStatus": "POSTED", "timeFrame": "Baseline and 12 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers."}, {"id": "OG001", "title": "Polypill", "description": "The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.\n\nPolypill will be taken once daily.\n\nPolypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "For the duration of the study period (Dec 2015 through June 2018) and for each participant's 12-month period of participation", "eventGroups": [{"id": "EG000", "title": "Usual Care", "description": "Subjects in this arm will not receive any investigational medications. They will continue to receive usual medical care, as directed by their primary care providers.", "deathsNumAffected": 2, "deathsNumAtRisk": 155, "seriousNumAffected": 3, "seriousNumAtRisk": 155, "otherNumAffected": 0, "otherNumAtRisk": 155}, {"id": "EG001", "title": "Polypill", "description": "The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.\n\nPolypill will be taken once daily.\n\nPolypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)", "deathsNumAffected": 2, "deathsNumAtRisk": 148, "seriousNumAffected": 2, "seriousNumAtRisk": 148, "otherNumAffected": 0, "otherNumAtRisk": 148}], "seriousEvents": [{"term": "non-CV death", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 155}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 148}]}, {"term": "non-CV death", "organSystem": "Hepatobiliary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "alcohol toxicity", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 155}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 148}]}, {"term": "stroke-related death", "organSystem": "Vascular disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 148}]}, {"term": "death from motor vehicle accident", "organSystem": "Social circumstances", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 148}]}, {"term": "Coronary Artery Bypass Surgery", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 155}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 148}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Thomas J Wang", "organization": "UT southwestern", "email": "thomas.wang@UTsouthwestern.edu", "phone": "6159361717"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2016-12-28", "uploadDate": "2019-06-25T13:53", "filename": "Prot_SAP_000.pdf", "size": 586123}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006949", "term": "Hyperlipidemias"}], "ancestors": [{"id": "D000050171", "term": "Dyslipidemias"}, {"id": "D000052439", "term": "Lipid Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "relevance": "LOW"}, {"id": "M10000", "name": "Hyperlipidemias", "asFound": "Hyperlipidemia", "relevance": "HIGH"}, {"id": "M10002", "name": "Hyperlipoproteinemias", "relevance": "LOW"}, {"id": "M26181", "name": "Dyslipidemias", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M27029", "name": "Lipid Metabolism Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "D000069059", "term": "Atorvastatin"}], "ancestors": [{"id": "D000000924", "term": "Anticholesteremic Agents"}, {"id": "D000000960", "term": "Hypolipidemic Agents"}, {"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000057847", "term": "Lipid Regulating Agents"}, {"id": "D000019161", "term": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}], "browseLeaves": [{"id": "M351", "name": "Atorvastatin", "asFound": "General", "relevance": "HIGH"}, {"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M21701", "name": "Losartan", "asFound": "Staff", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M4243", "name": "Anticholesteremic Agents", "relevance": "LOW"}, {"id": "M4278", "name": "Hypolipidemic Agents", "relevance": "LOW"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M28883", "name": "Lipid Regulating Agents", "relevance": "LOW"}, {"id": "M21155", "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Lipd", "name": "Lipid Regulating Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}